Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Agenus Inc AGEN

Healthcare Biotechnology
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.


NDAQ:AGEN - Post by User

Agenus Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by PressReleaseon Oct 08, 2024 5:44pm
1 Views
Post# 36258522

New Press Release - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

New Press Release - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Agenus between January 23, 2023 and July 17, 2024 and would like...read article.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities